Loading...
NPI 1619367679 · San Diego, CA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Birdrock is a clinical medical laboratory provider located in San Diego, California. This profile covers 61 Medicare and 69 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Birdrock |
| Address | 8430 Juniper Creek Ln |
| City | San Diego |
| State | CA |
| ZIP | 92126 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | January 29, 2015 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $6.2M |
| Medicaid | $3.2M |
Payer mix and scale: BIRDROCK reports $6.2M in total Medicare revenue and $3.2M in total Medicaid revenue, so Medicare is the larger payer relationship by reported revenue while Medicaid is also a meaningful revenue stream. Both payers appear active for this entity rather than it being effectively single‑payer, with Medicare roughly double the Medicaid revenue on file ($6.2M vs. $3.2M).
Revenue concentration by payer: Revenue is highly concentrated on a few codes for each payer — the top three Medicare codes account for 55.7% of total Medicare revenue and the top three Medicaid codes account for 63.9% of total Medicaid revenue. For Medicare those top three codes are 87798 ($1.8M, 31.1%), G0482 ($806.5K, 14.3%), and G0483 ($580.8K, 10.3%); for Medicaid the top three are G0483 ($993.4K, 33.3%), 87798 ($501.9K, 16.8%), and G0482 ($411.3K, 13.8%).
Service-line profile: The CPT/HCPCS mix shows a dual focus on molecular infectious-agent testing and definitive drug testing. High-revenue molecular/amplified probe codes (87798, 87150, 87481, 87653, 87640/87641, U0003, 87631) alongside G0482/G0483 and related definitive drug-test codes indicate an operation built around nucleic-acid amplification assays and GC/MS or LC/MS drug-identification workflows rather than only routine chemistry or anatomic pathology panels.
Medicare competitive standing: BIRDROCK is a national high-volume reporter on several Medicare line items — for 87798 it ranks #36 of 1319 providers nationally (97th percentile) and is described as notably above typical national volume for this code, and for G0482 it ranks #11 of 1618 providers nationally (99th percentile) though annotated as typical, unremarkable volume for that code. This pattern suggests the lab is a nationally prominent biller for certain molecular tests while the marketplace for definitive drug testing has many high-volume peers.
Medicaid (in‑state) competitive standing: Within California the provider shows leadership on a subset of tests used by state programs — G0483 is 33.3% of Medicaid revenue (16.6K claims, $993.4K) and ranks #12 of 99 in-state (89th percentile), while 87150 ranks #3 of 81 in-state (98th percentile) and 87640 ranks #3 of 95 in-state (98th percentile) with both 87150 and 87640 described as high-volume in-state. These rank and percentile positions indicate BIRDROCK is a major in-state participant for several molecular and microbiology assays used by Medicaid.
High transactional volume across low- and higher-paid tests: The Medicare file shows very high claim counts on certain low-dollar molecular tests (e.g., 87798: 51.7K claims at $34/claim) together with thousands of higher-paid definitive drug-test claims (e.g., G0482: 4.1K claims at $195/claim; G0483: 2.4K claims at $242/claim). On Medicaid there are similarly large claim volumes for drug-screening and presumptive panels (e.g., 80307: 19.8K claims) and for G0483 (16.6K claims), indicating throughput-driven revenue that mixes many lower‑unit-dollar NAAT assays with fewer, higher‑unit-dollar mass‑spec drug identifications.
Statistical outliers and notable code-level signals: Multiple codes are flagged as above-typical in their peer sets — Medicare 87798 is described as notably above typical national volume, and several amplified probe assays (Medicare 87653, 87640, 87641 and Medicaid 87653, 87640) are described as notably above typical volume in their respective peer groups. Conversely, some high-revenue drug-testing codes (e.g., Medicare G0482, G0483) are listed with very high national ranks but annotated as typical, unremarkable volume for those codes, suggesting the provider’s drug-testing services are large but sit in a widely distributed competitive field.
Tenure and operational maturity: The provider’s NPI was enumerated on 2015-01-29 (~11 years ago), indicating an established operational history at least since that enumeration date. Combined with multi-year billing traction across both Medicare and Medicaid and the concentration on specialized molecular and definitive drug-testing codes, the pattern is consistent with an established clinical laboratory focused on molecular diagnostics and toxicology services.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
61 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 51,710 | $30 | $1.8M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 4,140 | $200 | $806.5K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2,400 | $240 | $580.8K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 16,900 | $30 | $574.6K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 10,410 | $30 | $353.9K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 3,380 | $60 | $206.2K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 5,170 | $30 | $175.8K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 1,200 | $140 | $167.6K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 4,850 | $30 | $164.8K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 4,410 | $30 | $150K |
Showing 1–10 of 61
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 61 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
61 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| G0482 | 4 | 30 | 70 | $190 | $555.9K |
| G0483 | 13 | 70 | 360 | $240 | $427.9K |
| 87798 | 6 | 110 | 1,340 | $30 | $338.2K |
| U0003 | 58 | 130 | 730 | $70 | $246.4K |
| 87150 | 3 | 30 | 1,690 | $30 | $222.6K |
| G0481 | 33 | 50 | 250 | $150 | $131.2K |
| G2023 | 45 | 90 | 1,030 | $20 | $110.9K |
| U0005 | 65 | 150 | 780 | $20 | $75.1K |
| 87481 | 4 | 100 | 270 | $30 | $72.7K |
| 80307 | 10 | 150 | 220 | $60 | $69.2K |
Showing 1–10 of 61
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
69 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 16,560 | $60 | $993.4K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 8,370 | $60 | $501.9K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 4,960 | $80 | $411.3K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 19,840 | $20 | $317.5K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 12,120 | $10 | $96.9K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 2,700 | $30 | $78.2K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 5,610 | $10 | $72.9K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 6,540 | $10 | $72K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 6,130 | $10 | $67.4K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 5,650 | $10 | $56.5K |
Showing 1–10 of 69
How this provider's Medicaid billing volume and revenue compare to other California providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. California median
69 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 9 | 60 | 370 | $80 | $4.1M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 12 | 100 | 520 | $120 | $2.4M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 12 | 70 | 650 | $70 | $1.6M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 229 | 750 | 950 | $50 | $890K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 188 | 250 | 800 | $110 | $625.7K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 113 | 150 | 580 | $60 | $608.7K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 32 | 660 | 1,490 | $30 | $417.2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 319 | 340 | 970 | $40 | $343.6K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 478 | 1,140 | 530 | $20 | $195.6K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 381 | 1,270 | 450 | $20 | $183.5K |
Showing 1–10 of 69
Other providers in the same ZIP code as Birdrock, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Tommy Ngo | CA | Physical Therapist | $121.8K | $0 |
| Anthony Chang | CA | Diagnostic Radiology Physician | $90.9K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.